Literature DB >> 29358780

Gastrointestinal cancer: Novel promising first-line combination.

Diana Romero.   

Abstract

Entities:  

Year:  2018        PMID： 29358780     DOI： 10.1038/nrclinonc.2018.7

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.

Authors:  Y Yamada; T Denda; M Gamoh; I Iwanaga; S Yuki; H Shimodaira; M Nakamura; T Yamaguchi; H Ohori; K Kobayashi; M Tsuda; Y Kobayashi; Y Miyamoto; M Kotake; K Shimada; A Sato; S Morita; S Takahashi; Y Komatsu; C Ishioka
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.